AbTx is a biotech firm developing next-generation antibody-drug conjugates with enzymatic precision for oncology.
AbTx has raised $1.9M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
AbTx's investors include PMT - Microtechnology Hub, Santenov Dijon Bourgogne, Capital Cell, Bpifrance Digital Venture, DECA-BFC.
AbTx is headquartered in Dijon, France.
AbTx is a biotech firm developing next-generation antibody-drug conjugates with enzymatic precision for oncology.
AbTx is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AbTx — Funding & Investors." VCBacked, September 17, 2026, https://www.vcbacked.co/company/abtx. Accessed October 1, 2026.
VCBacked. (2026). AbTx — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/abtx
{{cite web |title=AbTx — Funding & Investors |url=https://www.vcbacked.co/company/abtx |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated